Edward H Wood1, Peter H Tang2, Irina De la Huerta1, Edward Korot3, Stephanie Muscat4, Daniel A Palanker2, George A Williams1,3. 1. Associated Retinal Consultants, Royal Oak, Michigan. 2. Department of Ophthalmology, Hansen Experimental Physics Laboratory, Stanford University, Stanford, California. 3. Oakland University William Beaumont School of Medicine, Rochester, Michigan. 4. Stanford University, Stanford, California.
Abstract
PURPOSE: To review and discuss current innovations and future implications of promising biotechnology and biomedical offerings in the field of retina. We focus on therapies that have already emerged as clinical offerings or are poised to do so. METHODS: Literature review and commentary focusing on stem cell therapies, gene-based therapies, optogenetic therapies, and retinal prosthetic devices. RESULTS: The technologies discussed herein are some of the more recent promising biotechnology and biomedical developments within the field of retina. Retinal prosthetic devices and gene-based therapies both have an FDA-approved product for ophthalmology, and many other offerings (including optogenetics) are in the pipeline. Stem cell therapies offer personalized medicine through novel regenerative mechanisms but entail complex ethical and reimbursement challenges. CONCLUSION: Stem cell therapies, gene-based therapies, optogenetics, and retinal prosthetic devices represent a new era of biotechnological and biomedical progress. These bring new ethical, regulatory, care delivery, and reimbursement challenges. By addressing these issues proactively, we may accelerate delivery of care to patients in a safe, efficient, and value-based manner.
PURPOSE: To review and discuss current innovations and future implications of promising biotechnology and biomedical offerings in the field of retina. We focus on therapies that have already emerged as clinical offerings or are poised to do so. METHODS: Literature review and commentary focusing on stem cell therapies, gene-based therapies, optogenetic therapies, and retinal prosthetic devices. RESULTS: The technologies discussed herein are some of the more recent promising biotechnology and biomedical developments within the field of retina. Retinal prosthetic devices and gene-based therapies both have an FDA-approved product for ophthalmology, and many other offerings (including optogenetics) are in the pipeline. Stem cell therapies offer personalized medicine through novel regenerative mechanisms but entail complex ethical and reimbursement challenges. CONCLUSION: Stem cell therapies, gene-based therapies, optogenetics, and retinal prosthetic devices represent a new era of biotechnological and biomedical progress. These bring new ethical, regulatory, care delivery, and reimbursement challenges. By addressing these issues proactively, we may accelerate delivery of care to patients in a safe, efficient, and value-based manner.
Authors: Jamie M Sperger; Xin Chen; Jonathan S Draper; Jessica E Antosiewicz; Chris H Chon; Sunita B Jones; James D Brooks; Peter W Andrews; Patrick O Brown; James A Thomson Journal: Proc Natl Acad Sci U S A Date: 2003-10-31 Impact factor: 11.205
Authors: Micha Drukker; Gil Katz; Achia Urbach; Maya Schuldiner; Gal Markel; Joseph Itskovitz-Eldor; Benjamin Reubinoff; Ofer Mandelboim; Nissim Benvenisty Journal: Proc Natl Acad Sci U S A Date: 2002-07-11 Impact factor: 11.205
Authors: R E MacLaren; R A Pearson; A MacNeil; R H Douglas; T E Salt; M Akimoto; A Swaroop; J C Sowden; R R Ali Journal: Nature Date: 2006-11-09 Impact factor: 49.962
Authors: Ana B Garcia-Delgado; Lourdes Valdes-Sanchez; Maria Jose Morillo-Sanchez; Beatriz Ponte-Zuñiga; Francisco J Diaz-Corrales; Berta de la Cerda Journal: Orphanet J Rare Dis Date: 2021-05-17 Impact factor: 4.123
Authors: Rachel A Care; Ivan A Anastassov; David B Kastner; Yien-Ming Kuo; Luca Della Santina; Felice A Dunn Journal: Cell Rep Date: 2020-06-09 Impact factor: 9.423
Authors: M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan Journal: Hum Genet Date: 2021-07-30 Impact factor: 4.132
Authors: Rachael Theresa Richardson; Michael R Ibbotson; Alexander C Thompson; Andrew K Wise; James B Fallon Journal: Healthc Technol Lett Date: 2020-06-25